New York State Teachers Retirement System Sells 15,203 Shares of Moderna, Inc. (NASDAQ:MRNA)

New York State Teachers Retirement System decreased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 265,985 shares of the company's stock after selling 15,203 shares during the quarter. New York State Teachers Retirement System owned 0.07% of Moderna worth $7,541,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock worth $776,075,000 after buying an additional 1,282,469 shares in the last quarter. Theleme Partners LLP raised its holdings in shares of Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock worth $303,819,000 after purchasing an additional 72,028 shares during the period. Geode Capital Management LLC raised its holdings in shares of Moderna by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after purchasing an additional 171,774 shares during the period. Invesco Ltd. raised its holdings in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock worth $208,169,000 after purchasing an additional 979,858 shares during the period. Finally, Norges Bank bought a new stake in shares of Moderna in the 4th quarter worth approximately $163,833,000. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

MRNA opened at $30.47 on Friday. The company has a fifty day moving average price of $26.72 and a 200-day moving average price of $31.45. The firm has a market capitalization of $11.78 billion, a P/E ratio of -3.49 and a beta of 1.84. Moderna, Inc. has a one year low of $23.15 and a one year high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The business's revenue for the quarter was down 35.3% on a year-over-year basis. During the same period in the previous year, the business earned ($3.07) EPS. On average, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MRNA shares. Barclays lowered their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada lowered their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Evercore ISI reduced their price objective on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. UBS Group reduced their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, William Blair reiterated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $46.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.